The decision by Ladenburg Thalmann to maintain a Buy rating and double the price target for Aileron Therapeutics indicates a strong positive outlook on the company's future performance. This significant increase in the price target reflects an optimistic assessment of Aileron's potential, likely based on recent developments or financial performance that could positively influence investor sentiment and drive the stock price higher in the short term.